Regulatory CMC Filing of Lipids for LNPs

(CordenPharma Graphic) Lipid Nanoparticle Structure – Composed of Payload (RNA/DNA), Helper Lipid, Sterol, Stabilizer and Ionizable Cationic (Novel) Lipid.

Delivering RNA or DNA effectively into target cells is a major challenge in genomic medicine. Lipid Nanoparticles (LNPs) have emerged as a leading non-viral delivery system, with ongoing research focused on optimizing their components and exploring novel lipid structures to improve efficiency, stability, and biocompatibility.

Are you working on novel lipids to overcome LNP delivery challenges and/or as an alternative to licensing? Are you familiar with the regulatory framework to get your novel lipid(s) into the clinic?

This summary helps LNP-based therapeutic innovators understand the regulatory landscape and supplier requirements for advancing their LNP formulations containing novel lipids into clinical development.

Key challenges in CMC filing of lipids for LNPs & Liposomes

Definition and classification of novel lipids
Supplier and manufacturing considerations for clinical readiness
Regulatory pathway for the approval of novel lipid-based formulations

What is considered a novel lipid?

A novel lipid is an inactive ingredient that is either 1) not previously used in approved drug products or 2) used in a new way, such as a different function, route of administration, or formulation, and thus lacks a proven safety record. This article focuses on novel lipids that are new chemical entities not listed in the FDA’s Inactive Ingredient Database (IID). For these, detailed safety and quality data must be submitted to the FDA to support marketing authorization, making regulatory understanding essential for successful approval.

Regulatory approval pathway of a novel lipid

To advance a novel lipid into clinical development, securing a GMP-compliant supply is essential. This requires partnering with a CDMO that manufactures lipid under GMP standards and has the analytical capabilities to ensure purity and consistency. The full development process includes manufacturing, sourcing raw materials, assessing stability, characterizing impurities, and establishing analytical methods.

Regulatory submissions follow the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Common Technical Document (CTD) format, particularly Modules 2 and 3, which require detailed information on manufacturing, characterization, and safety. CordenPharma uses this format to compile the Chemistry, Manufacturing, and Controls (CMC) sections for novel lipids.

(CordenPharma Graphic) – The Common Technical Document (CTD), with guidance for novel lipids given in Modules 2 and 3.

GMP vs. Non-GMP grade lipids

Because sourcing GMP-grade lipids is necessary for clinical studies, understanding the distinction between GMP and non-GMP (or R&D grade) lipids is critical. Our specialized lipid experts apply the same rigor in developing standard and custom lipids as we do drug substances. GMP standards for novel lipids are guided by ICH Q7 and Q11, which provide international principles for manufacturing active pharmaceutical ingredients. These guidelines cover all aspects of production, from quality management and equipment to documentation and validation, and become increasingly important as development progresses from R&D to commercial GMP-grade substances.

At CordenPharma, GMP principles are applied throughout the lifecycle of any lipid, from R&D to GMP scale, but there will be differences based on the phase of development. While R&D lipids are tested and documented, they are not held to specific release criteria and are clearly labeled as unsuitable for human or veterinary use.

In contrast, GMP-grade lipids undergo more rigorous testing, must meet defined specifications, and are accompanied by a Certificate of Analysis. These lipids also have a retest date and are evaluated for microbial and endotoxin levels to ensure safety in injectable LNP formulations.

What level of information is required for the CMC excipient sections of Module 3 for a novel lipid?

Because module 3 of the Common Technical Document (CTD) requires detailed information for both drug substances and drug products, novel lipids are treated similarly to drug substances from a CMC perspective. As clinical development progresses from Phase I to Phase III, the documentation must evolve as well, e.g. starting with qualified analytical methods and advancing to validated ones. The lipid manufacturing process must be described, with critical parameters identified and refined over time. Before commercialization, a Process Performance Qualification is also required to ensure consistent production quality.

How is safety on a novel lipid assessed?

The Investigational New Drug (IND) FDA application in the US, or Clinical Trial Application (CTA) in Europe, including Investigational Medicinal Product Dossier (IMPD) Sections, must contain sufficient information to demonstrate that the lipids composed as part of the LNP drug product are safe for human use. While the chemical structure of the lipids and impurities will be reviewed for any alerting structures, the overall safety of the lipids will be assessed as part of the final LNP drug product.

What about impurities?

CordenPharma aims to produce highly pure lipids, but any impurities above qualification thresholds must be thoroughly evaluated and characterized. Safety assessments follow ICH guidelines Q3A–Q3D, which address organic and inorganic impurities, residual solvents, and elemental contaminants. Genotoxic and mutagenic impurities receive special attention under ICH M7, with particular focus on controlling Nitrosamines through careful management of raw materials, processing conditions, and analytical characterization.

Drug Master File

A Drug Master File (DMF) submitted to the FDA allows confidential details about a facility, process, and materials for novel excipients or drug substances to be securely referenced in regulatory filings. The DMF holder provides a Letter of Authorization (LoA) to applicants, maintaining confidentiality between parties.

CordenPharma has nearly four decades of experience in preparing all the necessary documentation to support a DMF for novel lipids, using Section 3.2.A.3 of the ICH Common Technical Document (CTD) to detail excipient information. This data is compiled in a dossier, a structured collection of documents submitted to regulatory authorities, which often references one or more DMFs for both drug substances and novel excipients.

Conclusion

When progressing your LNP formulation that contains a novel lipid to the clinic, it is important to work with a CDMO that not only has proven experience manufacturing highly pure products but understands the regulatory process to ensure clinical approval for the efficient and safe delivery of your commercial therapy to market. Drawing upon an integrated global network from drug substance to drug products, including robust LNP formulation and aseptic fill-finish injectable drug product capabilities, CordenPharma is the CDMO partner you need to help your novel lipid-based LNP project navigate and progress along the regulatory pathway towards clinical approval.